Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-Authorisation Safety Study Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta

NCT04253015 is registered in ClinicalTrials.gov with RECORDATI GROUP as lead sponsor.

NCT NCT04253015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04253015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-Authorisation Safety Study Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta
Lead sponsor
RECORDATI GROUP
Phase
Observational
Overall status
Active, not recruiting
Start date
September 30, 2019
Completion date
June 30, 2036
Enrollment
125 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma